tbuckley/cabot-search huggingface dataset:
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML).
Authors: Masamichi Mori, Naoki Kaneko, Yoko Ueno, Ruriko Tanaka, Kathy Cho, Rika Saito, Yutaka Kondoh, Itsuro Shimada, Sadao Kuromitsu
Journal: Journal of Clinical Oncology (2014)

7070 Background: Activating mutations in FLT3 receptor tyrosine kinase, characterized by internal tandem duplication (ITD) and tyrosine kinase domain point mutations near position D835, have been identified in up to 30% of AML patients. These mutations are associated with poor prognosis. ASP2215 is a novel small molecule tyrosine kinase inhibitor, currently under clinical trial evaluation. Methods: The kinase inhibition profile was investigated using enzyme assays. Antiproliferative activity was evaluated against several AML cell lines with assessment of the inhibition of pFLT3 and downstream molecules using Western blot and flow cytometry. Antitumor activity was evaluated in nude mice transplanted with MV4-11 AML cells. The pharmacokinetics in xenografted mice was also investigated. Results: Of the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 also inhibited the growth of Ba/F3 cells expressing FLT3-ITD and/or FLT3-D835 mutation with similar activity. Colony formation of human granulocyte-macrophage decreased to 58% in response to ASP2215 at 100 nM, more than 100-fold higher than required for MV4-11. In MV4-11 xenografted-mice, the concentration of ASP2215 in tumors was more than 20-fold higher than that in plasma with oral administration of ASP2215 at 10 mg/kg for 4 days. Treatment of ASP2215 for 28 days resulted in dose-dependent inhibition of MV4-11 tumor growth and induced complete tumor regression at more than 6 mg/kg. Further, ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. Conclusions: ASP2215, a FLT3/AXL inhibitor, showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. These findings support the development of ASP2215 for the potential use in treating AML.
Effects of Transjugular Intrahepatic Portosystemic Shunt (Tips) on Blood Volume Distribution in Patients with Cirrhosis
Authors: T.M. Busk, F. Bendtsen, J.H. Henriksen, S. Fuglsang, F.S. Larsen, J.O. Clemmesen, S. Møller
Journal: Journal of Hepatology (2016)
2016 Presidential Address: Diabetes at 212°—Confronting the Invisible Disease
Authors: Desmond Schatz
Journal: Diabetes Care (2016)

This address was delivered by Desmond Schatz, MD, President, Medicine & Science, of the American Diabetes Association (ADA), at the Association's 76th Scientific Sessions in New Orleans, LA, on 12 June 2016. Dr. Schatz is Professor and Associate Chairman of Pediatrics, Medical Director of the University of Florida Diabetes Institute, and Director of the Clinical Research Center at the University of Florida, Gainesville, FL. A physician-scientist, he has been involved in type 1 diabetes research since the mid-1980s and has published over 300 articles and book chapters. Dr. Schatz's research focuses on the prediction, natural history, genetics, immunopathogenesis, and prevention of type 1 diabetes, as well as the treatment of children and adolescents with type 1 diabetes. He is the principal investigator on several National Institutes of Health, JDRF, and other competitively funded grants. Dr. Schatz earned his medical degree from the University of the Witwatersrand School of Medicine in Johannesburg, South Africa, and completed his residency and fellowship at the University of Florida. He has been an ADA volunteer for over 30 years and has served on the Professional Practice Committee (twice), Scientific Sessions Meeting Planning Committee, Publications Policy Committee (Chair), Government Relations Committee, Youth Strategies Committee, and Board of Directors. A board-certified pediatric endocrinologist, Dr. Schatz is the 2016 recipient of the Banting Medal for Leadership and Service from the ADA for his outstanding commitment and contributions to the Association.
Human Leucocyte Antigen Associations in IGG4-Related Disease and Primary Sclerosing Cholangitis Stratified by IGG4 Levels, in a Multicenter UK Cohort
Authors: E.L. Culver, J.M. Hurst, T. Cargill, D. Joshi, D. Nayar, M. Huggett, K. Oppong, S. Savic, A. Bateman, R.W. Chapman, G.J. Webster, E. Barnes
Journal: Journal of Hepatology (2016)
Photodynamic therapy using topical methyl aminolaevulinate versus cryotherapy for treatment of primary superficial basal cell carcinoma : results of a five-year prospective randomized trial
Authors: N Basset-Séguin, L Ibbotson, L Emtestam, M Tarstedt, C Morton, M Maroti, P Calzavara Pinton, S Varma, Rik Roelandts, P Wolf
Journal: British Journal of Dermatology (2006)
In Silico Identification and in Vivo Validation of Non-Invasive Biomarkers for Liver Fibrosis
Authors: P.J. Giraudi, S.E. Gambaro, C.M. Chackelevicius, M. Giuricin, L.S. Crocè, D. Bonazza, G. Soardo, N. de Manzini, C. Tiribelli, S. Palmisano, N. Rosso
Journal: Journal of Hepatology (2016)
Tips versus Endoscopy plus Propranolol and Anticoagulation For Variceal Rebleeding in Cirrhotic Patients with Portal Vein Thrombosis: Results of a Randomized Controlled Trial
Authors: X. Qi, C. He, Z. Yin, Z. Wang, H. Zhang, H. Xie, L. Yao, J. Wang, J. Xia, H. Cai, Z. Yang, M. Bai, W. Guo, J. Niu, Kaichun Wu, Daiming Fan, G. Han
Journal: Journal of Hepatology (2016)
Outbreak of trichinellosis related to eating imported wild boar meat, Belgium, 2014
Authors: Peter Messiaen, Annemie Forier, Steven Vanderschueren, Caroline Theunissen, Jochen Nijs, Marjan Van Esbroeck, Emmanuel Bottieau, Koen De Schrijver, Inge C Gyssens, Reinoud Cartuyvels, Pierre Dorny, Jeroen van der Hilst, Daniel Blockmans
Journal: Eurosurveillance (2016)

Trichinellosis is a rare parasitic zoonosis caused by Trichinella following ingestion of raw or undercooked meat containing Trichinella larvae. In the past five years, there has been a sharp decrease in human trichinellosis incidence rates in the European Union due to better practices in rearing domestic animals and control measures in slaughterhouses. In November 2014, a large outbreak of trichinellosis occurred in Belgium, related to the consumption of imported wild boar meat. After a swift local public health response, 16 cases were identified and diagnosed with trichinellosis. Of the 16 cases, six were female. The diagnosis was confirmed by serology or the presence of larvae in the patients’ muscle biopsies by histology and/or PCR. The ensuing investigation traced the wild boar meat back to Spain. Several batches of imported wild boar meat were recalled but tested negative. The public health investigation allowed us to identify clustered undiagnosed cases. Early warning alerts and a coordinated response remain indispensable at a European level.
Differences between Hepatitis HCV-Monoinfected and HCV-HIV-Coinfected Patients Treated with New Daa-Based Therapies
Authors: M.L. Montes, A. Ahumada, T. Aldamiz, A. Olveira, L. Bailón, J. García-Samaniego, J. Berenguer, D. Perez-Valderas, V. Moreno, P. Miralles, P. Castillo, D. Rincón, E. Valencia, M. Romero, J. de Quirós, L.B. Carlos, M.V. Catalina, A. Garcia, F. Parras, A. Matilla, M. Abadía, M. Rico, L. Martin-Carbonero
Journal: Journal of Hepatology (2016)
Inhibition of Eg5 (kinesin-like 1) with Antisense Oligonucleotides leads to cell-cycle arrest in G2/M and antitumor activity against xenograft tumors
Authors: Stephanie S. Propp, Erich Koller, Ming Yi Chang, Robert I. Glazer, Scott Hirsch, Peter Shepard, Seongjoon Koo, Cain Murphy, Nicholas Dean
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

4426 

Cancer is the result of perturbed cell-cycle progression. Many of the current cancer therapies are aimed at controlling this aberrant cellular growth. Here, we utilized a high-throughput screening assay to search for new drug targets. The assay uses 2’-methoxyethyl modified antisense oligonucleotides (ASOs) designed to 1500 different genes. Different tumor cell lines were transfected with ASOs and then checked for phenotypic effects in a cell-cycle assay, with a particular emphasis on G2/M arrest. Our assay showed a G2/M increase for expected targets, such as cdc27, CDK1 and aurora-kinases. The ASO that had the largest G2/M-arrest seen in the cell-cycle assay targeted Eg5 (kinesin-like-1). Eg5 is a member of the kinesin family of motor proteins, and is known to play a role in centrosome separation and assembly of the mitotic spindle. Inhibiting Eg5 by ASO treatment resulted in a strong G2/M arrest across a broad array of tumor cell types. The treatment also led to a reduction of Eg5 mRNA and protein levels, a reduction in cellular proliferation, and subsequently led to an increase in apoptosis. Eg5 ASO treatment produced the expected aberrations in DNA segregation. Inhibiting Eg5 also produced alterations in other cell-cycle regulatory proteins, most notably survivin, aurora A and phospho-histone H3. This further supports the phenotypic effect seen in the cell-cycle. In addition, we used a cancer profiling array to show that there is a significant increase in Eg5 expression in tumors from breast, lung, ovary and uterus, as compared to normal adjacent tissue. The strength of the in vitro data then led us to believe that the Eg5 ASO would have potent anti-tumor properties in vivo . Two different tumor xenograft models were utilized to test the Eg5 ASO; U87-MG, a glioblastoma, and MDA-MB-231, a breast tumor carcinoma. The treatment with Eg5 ASO led to a statistically significant reduction of tumor growth in both xenograft models. To assess the safety of treating with Eg5 ASO, normal mice were dosed with a mouse specific Eg5 ASO at 25 and 50 mg/kg twice a week for eight weeks. The treatment did not result in any apparent toxicity, e.g. animal weights, liver transaminases, gastrointestinal appearances and bone marrow abnormalities. The strength of this data package leads us to believe that Eg5 is a viable target for drug development to treat cancer.
The Genetic Landscape of Renal Complications in Type 1 Diabetes
Authors: Niina Sandholm, Natalie Van Zuydam, Emma Ahlqvist, Thorhildur Juliusdottir, Harshal A. Deshmukh, N. William Rayner, Barbara Di Camillo, Carol Forsblom, Joao Fadista, Daniel Ziemek, Rany M. Salem, Linda T. Hiraki, Marcus Pezzolesi, David Trégouët, Emma Dahlström, Erkka Valo, Nikolay Oskolkov, Claes Ladenvall, M. Loredana Marcovecchio, Jason Cooper, Francesco Sambo, Alberto Malovini, Marco Manfrini, Amy Jayne McKnight, Maria Lajer, Valma Harjutsalo, Daniel Gordin, Maija Parkkonen, Valeriya Lyssenko, Paul M. McKeigue, Stephen S. Rich, Mary Julia Brosnan, Eric Fauman, Riccardo Bellazzi, Peter Rossing, Samy Hadjadj, Andrzej Krolewski, Andrew D. Paterson, Joel N. Hirschhorn, Alexander P. Maxwell, Claudio Cobelli, Helen M. Colhoun, Leif Groop, Mark I. McCarthy, Per-Henrik Groop
Journal: Journal of the American Society of Nephrology (2016)

Diabetes is the leading cause of ESRD. Despite evidence for a substantial heritability of diabetic kidney disease, efforts to identify genetic susceptibility variants have had limited success. We extended previous efforts in three dimensions, examining a more comprehensive set of genetic variants in larger numbers of subjects with type 1 diabetes characterized for a wider range of cross-sectional diabetic kidney disease phenotypes. In 2843 subjects, we estimated that the heritability of diabetic kidney disease was 35% (P=6.4×10-3). Genome-wide association analysis and replication in 12,540 individuals identified no single variants reaching stringent levels of significance and, despite excellent power, provided little independent confirmation of previously published associated variants. Whole-exome sequencing in 997 subjects failed to identify any large-effect coding alleles of lower frequency influencing the risk of diabetic kidney disease. However, sets of alleles increasing body mass index (P=2.2×10-5) and the risk of type 2 diabetes (P=6.1×10-4) associated with the risk of diabetic kidney disease. We also found genome-wide genetic correlation between diabetic kidney disease and failure at smoking cessation (P=1.1×10-4). Pathway analysis implicated ascorbate and aldarate metabolism (P=9.0×10-6), and pentose and glucuronate interconversions (P=3.0×10-6) in pathogenesis of diabetic kidney disease. These data provide further evidence for the role of genetic factors influencing diabetic kidney disease in those with type 1 diabetes and highlight some key pathways that may be responsible. Altogether these results reveal important biology behind the major cause of kidney disease.
Radial versus Femoral Approach in Non-ST Elevation ACS: Lessons From EARLY
Authors: Marc W Klutstein, Cynthia M Westerhout, Sunil Rao, Basil S Lewis, C. Michael Gibson, Sohrab Lutchmedial, Petr Widimsky, P. Gabriel Steg, Anthony Dalby, Uwe Zeymer, Frans Van de Werf, Robert A Harrington, L. Kristin Newby, Paul W Armstrong
Journal: Circulation (2010)
Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Authors: A. Sanyal, Z. Goodman, S. Harrison, D.C. Rockey, A.M. Diehl, S. Caldwell, M.L. Shiffman, P. Thuluvath, R.P. Myers, G. Mani Subramanian, J.G. McHutchison, M.F. Abdelmalek, V. Ratziu, N. Afdhal, J. Bosch
Journal: Journal of Hepatology (2016)
Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study
Authors: Jie Liu, James A Platts-Mills, Jane Juma, Furqan Kabir, Joseph Nkeze, Catherine Okoi, Darwin J Operario, Jashim Uddin, Shahnawaz Ahmed, Pedro L Alonso, Martin Antonio, Stephen M Becker, William C Blackwelder, Robert F Breiman, Abu S G Faruque, Barry Fields, Jean Gratz, Rashidul Haque, Anowar Hossain, M Jahangir Hossain, Sheikh Jarju, Farah Qamar, Najeeha Talat Iqbal, Brenda Kwambana, Inacio Mandomando, Timothy L McMurry, Caroline Ochieng, John B Ochieng, Melvin Ochieng, Clayton Onyango, Sandra Panchalingam, Adil Kalam, Fatima Aziz, Shahida Qureshi, Thandavarayan Ramamurthy, James H Roberts, Debasish Saha, Samba O Sow, Suzanne E Stroup, Dipika Sur, Boubou Tamboura, Mami Taniuchi, Sharon M Tennant, Deanna Toema, Yukun Wu, Anita Zaidi, James P Nataro, Karen L Kotloff, Myron M Levine, Eric R Houpt
Journal: The Lancet (2016)
Clarifying the time frame and units of selection in the cultural group selection hypothesis
Authors: Andrew Whiten, David Erdal
Journal: Behavioral and Brain Sciences (2016)

Abstract We raise and discuss two issues for clarification. First, over what timescale is cultural group selection proposed to have been active? Unprecedented cooperation is inferred to have arisen in hunter-gather life well before the recent period on which Richerson et al. focus. Second, what is the unit of selection? Groups (of human individuals)? Or cultural entities along the lines of “meme-complexes”?
Accuracy of a Point Shear Wave Elastography Technique (ElastPQ) in the Non-Invasive Assessment of Liver Fibrosis in a Large Cohort of Liver Patients
Authors: M. Garcovich, M. Pompili, E. Di Stasio, B.E. Dyrda, L. Riccardi, M.E. Ainora, A. Grieco, G.L. Rapaccini, M. Siciliano, A. Gasbarrini, M.A. Zocco
Journal: Journal of Hepatology (2016)
PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC
Authors: Ticiana Leal, Heather Wakelee, Jeffrey Infante, George Blumenschein, Karen Reckamp, Corey Carter, Saiama Waqar, Jon Gockerman, Christine Lovly, Gary Dukart, Kimberly Harrow, Chris Liang, James Gibbons, Leora Horn
Journal: Journal of Thoracic Oncology (2016)
Phase I/II study of oral TS-1 and gemcitabine in elderly patients with advanced non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group 0502
Authors: T. Seto, T. Yamanaka, K. Eguchi, H. Okamoto, M. Shibuya, T. Ogura, T. Shinkai, Y. Takiguchi, N. Masuda, Y. Ichinose, K. Watanabe
Journal: Journal of Clinical Oncology (2007)

18137 Background: Optimal treatment for elderly patients with NSCLC has been under active investigation. This study evaluated the safety and initial efficacy of a novel combination regimen of oral fluoropyrimidine TS-1 plus gemcitabine (GEM) for elderly patients (pts) with advanced NSCLC. Methods: A phase I/II trial in 11 centers examined TS-1 and GEM in pts with age = 70, stage IIIB/IV previously untreated NSCLC. The starting dose was 60 mg/m 2 day (day 1–14) for TS-1 and 800 mg/m 2 for GEM (day 8, 15). GEM was increased to 1,000 mg/m 2 at dose level 2 and TS-1 was increased to 80 mg/mg 2 /day at dose level 3. Phase II portion of the study assessed the efficacy and tolerability of the combination regimen at the dose determined in the phase I portion. The primary endpoint was objective response rate. Results: Twenty two pts were enrolled in the phase I portion: 6 pts on dose level 1, 10 on dose level 2 and 6 on dose level 3. Median age of this group was 75 yrs (range 70–85). Dose limiting toxicities included Gr. 4 neutropenia (2 pts) and Gr.3 skin toxicity (4 pts). The recommended dose (RD) was TS-1 60 mg/day and GEM 1,000 mg/m 2 , with which 20 pts were subsequently treated in the phase II portion. The median age of 30 pts treated with the RD was 76 yrs (range 70–85). Grade (Gr) 3/4 toxicities include neutropenia (12 pts; 7 with Gr 4), thrombocytopenia (4 pts; 0 with Gr 4), skin toxicity (8 pts), thrombus (1 pt) and peumonitis (2 pts). Nine patients (30%, 95% confidence interval [CI] = 14 to 46%) had partial responses and 16 (53%, 95% CI = 35 to 71%) had stable disease. Conclusions: Encouraging antitumor activity and safety of TS-1 plus gemcitabine support further development of this combination therapy for elderly patients with advanced NSCLC. No significant financial relationships to disclose.
Epidemiologic study to evaluate the treatment of palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD).
Authors: M. L. Gonzalvez, N. Diaz, A. Redondo, E. G. Calvo, J. J. Illarramendi, B. Munarriz, J. Del Campo, J. Castellanos Diez, A. Santaballa, G. Lopez-Vivanco
Journal: Journal of Clinical Oncology (2010)

e12014 Background: PLD is a highly active agent for OC and MBC. Liposome encapsulation and pegylation of PLD alters the pharmacokinetic and side effect (SE) profiles of conventional doxorubicin, improving its therapeutic ratio. PPE is a common SE of PLD and may be related to the pressure-dependent extravasation of liposomes into the skin. Methods: Pts with OC or MBC being treated with PLD were observed. The primary objectives were frequency of PPE as well as the curative pharmacologic and/or prophylactic treatment for PPE. Secondary objectives were numbers of pts that required change in PLD treatment dose/schedule due to PPE and pts compliance to PPE treatment. Results: 154 pts from 16 Spanish hospitals were evaluable. The mean age was 62.4 y (range: 39-83). 73 pts had MBC and 81 had OC. 140 pts (90.9%) received PLD monotherapy with a mean of 3.9 cycles. The mean accumulated dose and dose intensity of PLD were 95.4 mg/m2 (15-331.5) and 9.7 mg/m2/week (4.4-23.3), respectively. At time of study enrollment, 65 pts presented with PPE (grade 1 n = 42; grade 2 n = 15; grade 3 n = 8; no grade 4). The median duration of PPE was 23 days (0-226). PLD treatment was adjusted in 18 pts (11.7%): delayed in 10 pts and dose reduced (to mean of 35 mg/m2 [30-40]) in 8 pts. PLD had to be interrupted in 4 pts. 14 pts (9.1%) received curative therapy for PPE, 52 (33.8%) received prophylaxis, and 6 (3.9%) received both. Most pts (n=55, 76.4%) received one treatment for PPE. Common pharmacologic strategies were oral dexamethasone (n = 10; 71.4%), pyridoxine (n = 8, 57.1%), topical corticosteroids (n = 8, 57.1%), and topical DMSO 99% (n = 3, 21.4%). Nonpharmacologic strategies were avoid excessive heat/water (n = 14, 100%), keep skin hydrated (n = 12, 85.7%), avoid sweating and physical activity (n = 7, 50%), avoid tight fitting clothing (n = 12, 85.7%), and local cooling of hands/feet (n = 6, 42.9%). Compliance with each educational recommendation was low (< 45%). Conclusions: While PPE was an observed SE of PLD in these MBC and OC pts, it was manageable. Patient education to ensure compliance with PPE preventive measures and treatments is important in controlling this SE. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough
Novel Findings Support a Patophysiological Role of the Arachidonic Cascade in Hodgkin Lymphoma.
Authors: Jan Sjoberg, Frida Schain, Ylva Tryselius, Linda Backman, Anna Porwit, Cheng Liu, Dawei Xu, Wenbin Wei, Karl Baumforth, Paul Murray, Magnus Bjorkholm, Hans-Erik Claesson
Journal: Blood (2007)
Selective Intestinal Decontamination with Norfloxacin is Associated with an Increased Percentage of Regulatory T Cells and Serum IL-10 Levels
Authors: O.J. Juárez, I. Gómez-Hurtado, P. Zapater, A. Moratalla, J.M. González-Navajas, J. Such, R. Francés
Journal: Journal of Hepatology (2016)
Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development
Authors: Krzysztof Giannopoulos, Malgorzata Zajac, Olga Jankowska-Lecka, Joanna Zaleska, Joanna Purkot, Tomasz Gromek, Maria Soroka-Wojtaszko, Aneta Szudy-Szczyrek, Marek Hus, Lars Bullinger
Journal: Blood (2015)
The Incidence of Rethrombosis in Patients with Non-Cirrhotic, Non-Tumoral Chronic Portal Vein Thrombosis – A Prospective Observational Study
Authors: B. Procopet, G. Silva-Junior, E. Llop, A. Darnell, M.A. Garcia-Criado, F. Turon, A. Baiges, J.L. Calleja, J. Bosch, V. Hernandez-Gea, J.C. Garcia-Pagan
Journal: Journal of Hepatology (2016)
Can a Dose-Dense RCHOP-Like Regimen Be Effectively Used In a Community Setting? Results of a Phase II Study Employing Pegylated Liposomal Doxorubicin In Elderly (&gt; age 60) or Cardiac Compromised (LVEF &lt;45%) Patients with Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Stephen J. Noga, Judith Bosley, Pamela Nickoles
Journal: Blood (2010)
Combined Activity of NTCP and OATPS Governs Hepatic Uptake of Conjugated Bile Acids in Vivo
Authors: D. Slijepcevic, D. Tolenaars, D.R. de Waart, U. Beuers, R.O. Elferink, A. Schinkel, S. Van De Graaf
Journal: Journal of Hepatology (2016)
Abstract 16180: K-877, A Novel PPAR-alpha Selective Agonist, Suppresses Macrophage Activation and Arterial Lesion Formation
Authors: Hiroshi Iwata, Kentaro Murakami, Piero Ricchiuto, Sasha Singh, Alex C Mojcher, Peter Libby, Elena Aikawa, Masanori Aikawa
Journal: Circulation (2013)

Background: Macrophage activation contributes to the development of atherosclerotic vascular diseases and metabolic disorders. An emerging concept suggests that a microenvironment with dominance of...
Interferon-Free Treatment with Sofosbuvir Plus Daclatasvir Achieves Sustained Virologic Response in 100% of Difficult-To-Treat HIV/HCV-Coinfected Patients and Decreases Liver Stiffness
Authors: M. Mandorfer, on behalf of Vienna HIV & Liver Study Group, P. Schwabl, S. Steiner, B. Scheiner, D. Chromy, T. Bucsics, A.F. Staettermayer, M.C. Aichelburg, K. Grabmeier-Pfistershammer, M. Trauner, T. Reiberger, M. Peck-Radosavljevic
Journal: Journal of Hepatology (2016)
Nosology and Molecular Classification of Hepatocellular Adenomas
Authors: J.C. Nault, G. Couchy, P. Bioulac-Sage, Y. Bacq, J. Calderaro, V. Paradis, J. Ramos, J.-Y. Scoazec, E. Leteurtre, N. Sturm, C. Guettier, M. Fabre, E. Savier, L. Chiche, P. Labrune, J. Selves, D. Wendum, G. Morcrette, E. Gelabale, C. Pilati, A. Laurent, A. De Muret, J.-F. Blanc, B. Le Bail, S. Imbeaud, C. Balabaud, S. Rebouissou, J. Zucman-Rossi
Journal: Journal of Hepatology (2016)